The safety profile of the new different compounds tested for HER2-low BC is interestingly heterogeneous, according to the cytotoxic warhead, in the case of ADCs, or to the immunogenicity capacity, in the case of bispecific antibodies (Figure 2). The gene discussed is ERBB2; the disease is breast cancer.